Clinical impact on tuberculosis treatment outcomes of discordance between molecular and growth-based assays for Rifampin Resistance, California 2003-2013

Open Forum Infectious Diseases

Volumn 3, Issue 3, 2016, Pages

  Shah, Neha S ^a,b   Lin, Y G Grace ^b   Barry, Pennan M ^b   Cheng, Yi Ning ^c   Schecter, ^b,d   Gisela, ^b   Desmond, Ed ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b California Department of Health Tuberculosis Control Branch   (United States)

^c UNIVERSITY OF CALIFORNIA COOPERATIVE EXTENSION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Rifampin discordance; RpoB mutations; Tuberculosis

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CALIFORNIA; CHILD; DISCORDANT MUTATION; EXTRAPULMONARY TUBERCULOSIS; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; RECURRENCE RISK; RPOB MUTATION; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 85016018673     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw150     Document Type: Article

References (40)

1. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study. Am Rev Respir Dis 1981; 123:165-70.
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172:1169-227.
3. Espinal MA, Dye C, Raviglione M, Kochi A. Rational 'DOTS plus' for the control of MDR-TB. Int J Tuberc Lung Dis 1999; 3:561-3.
4. Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47:3501-6.
5. Van Deun A, Wright A, Zignol M, et al. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15:116-24.
6. Kahlmeter G, Brown DF, Goldstein FW, et al. European committee on antimicrobial susceptibility testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006; 12:501-3.
7. Werngren J, Sturegård E, Juréen P, et al. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012; 56:1253-7.
8. Schön T, Juréen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64:786-93.
9. Schön T, Juréen P, Chryssanthou E, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15:502-9.
10. ängeby K, Juréen P, Kahlmeter G, et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012; 90:693-8.
11. Kapur V, Li LL, Iordanescu S, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32:1095-8.
12. Telenti A, Honoré N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35:719-23.
13. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647-50.
14. Gillespie S. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46:267-74.
15. Johnson R, Streicher EM, Louw GE, et al. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8:97-111.
16. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.
17. Banerjee R, Allen J, Lin SY, et al. Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol 2010; 48:3779-81.
18. Lin SY, Desmond EP. Molecular diagnosis of tuberculosis and drug resistance. Clin Lab Med 2014; 34:297-314.
19. Rigouts L, Gumusboga M, de Rijk WB, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51:2641-5.
20. Van DA, Aung K, Hossain A, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015; 19:185-90.
21. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51:2633-40.
22. van Ingen J, Aarnoutse R, de Vries G, et al. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15:990-2.
23. Pang Y, Ruan YZ, Zhao J, et al. Diagnostic dilemma: treatment outcomes of tuberculosis patients with inconsistent rifampicin susceptibility. Int J Tuberc Lung Dis 2014; 18:357-62.
24. The World Health Organization. Treatment of Tuberculosis Guidelines, 4th Edition. Geneva: The World Health Organization, 2009. Reference number: WHO/HTM/TB/2009.420.
25. Ho J, Jelfs P, Sintchencko V. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother 2013; 68:2915-20.
26. Williamson DA, Roberts SA, Bower JE, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16:216-20.
27. Lin SY, Probert W, Lo M, Desmond E. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J Clin Microbiol 2004; 42:4204-8.
28. The World Health Organization. Definitions and reporting framework for tuberculosis. Geneva: The World Health Organization, 2013. Reference number: WHO/HTM/TB/2013.2.
29. Beavers S, Flood J, Weinfurter P, et al. Tuberculosis mortality in the United States: how can it be prevented? American Thoracic Society International Conference; San Francisco, California. 2012.
30. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52(RR11):1-77.
31. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9:737-46.
32. Harries AD, Satyanarayana S, Kumar AM, et al. Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review. Public Health Action 2013; 3(Suppl 1):S3-9.
33. Suwanpimolkul G, Grinsdale JA, Jarlsberg LG, et al. Association between diabetes mellitus and tuberculosis in United States-born and foreign-born populations in San Francisco. PLoS One 2014; 9:e114442.
34. Pascopella L, Barry PM, Flood J, DeRiemer K. Death with tuberculosis in California, 1994-2008. Open Forum Infect Dis 2014; 1:ofu090.
35. Pascopella L, DeRiemer K, Watt JP, Flood JM. When tuberculosis comes back: who develops recurrent tuberculosis in California? PLoS One 2011; 6:e26541.
36. Berrada ZL, Lin SY, Rodwell TC, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 2016; 85:177-81.
37. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10:662-5.
38. Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1853-7.
39. Peloquin C. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83.
40. The World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. Geneva: The World Health Organization, 2013 Reference number: WHO/HTM/TB/2013.16.